Table 2. Event Rates by Treatment Group and Severe Heart Failure Classification.
| Outcome | Omecamtiv mecarbil | Placebo | HR (95% CI) | ARR per 100 patient-years | P value | ||
|---|---|---|---|---|---|---|---|
| No./total No. (%) | Events per 100 patient-years | No./total No. (%) | Events per 100 patient-years | ||||
| Severe heart failure | |||||||
| Primary end point (time to first HF event or CV death) | 510/1106 (46.1) | 34.3 | 611/1152 (53.0) | 42.6 | 0.80 (0.71-0.90) | 8.3 | <.001 |
| CV death as first primary event | 107/1106 (9.7) | 7.2 | 142/1152 (12.3) | 9.9 | NA | NA | NA |
| HF hospitalization as first primary event | 385/1106 (34.8) | 25.9 | 441/1152 (38.3) | 30.8 | NA | NA | NA |
| Urgent outpatient visit as first primary event | 18/1106 (1.6) | 1.2 | 28/1152 (2.4) | 2.0 | NA | NA | NA |
| CV death | 288/1106 (26.0) | 15.5 | 332/1152 (28.8) | 17.3 | 0.88 (0.75-1.03) | 1.8 | .11 |
| HF hospitalization | 396/1106 (35.8) | 26.4 | 455/1152 (39.5) | 31.3 | 0.84 (0.74-0.97) | 4.8 | .02 |
| All-cause death | 375/1106 (33.9) | 20.2 | 416/1152 (36.1) | 21.7 | 0.92 (0.80-1.06) | 1.5 | .24 |
| No severe heart failure | |||||||
| Primary end point (time to first HF event or CV death) | 1013/3014 (33.6) | 21.1 | 996/2960 (33.6) | 21.3 | 0.99 (0.91-1.08) | 0.2 | .84 |
| CV death as first primary event | 239/3014 (7.9) | 5.0 | 229/2960 (7.7) | 4.9 | NA | NA | NA |
| HF hospitalization as first primary event | 722/3014 (24.0) | 15.0 | 692/2960 (23.4) | 14.8 | NA | NA | NA |
| Urgent outpatient visit as first primary event | 52/3014 (1.7) | 1.1 | 75/2960 (2.5) | 1.6 | NA | NA | NA |
| CV death | 520/3014 (17.3) | 9.3 | 466/2960 (15.7) | 8.5 | 1.10 (0.97-1.25) | –0.8 | .14 |
| HF hospitalization | 746/3014 (24.8) | 15.4 | 724/2960 (24.5) | 15.3 | 1.01 (0.91-1.12) | –0.1 | .88 |
| All-cause death | 692/3014 (23.0) | 12.4 | 649/2960 (21.9) | 11.9 | 1.05 (0.94-1.17) | –0.6 | .37 |
Abbreviations: ARR, absolute risk reduction; CV, cardiovascular; HF, heart failure; HR, hazard ratio; NA, not applicable.